GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Cyclically Adjusted PS Ratio

Glenmark Pharmaceuticals (NSE:GLENMARK) Cyclically Adjusted PS Ratio : 3.94 (As of Jul. 10, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2025-07-10), Glenmark Pharmaceuticals's current share price is ₹1818.80. Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹461.86. Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 3.94.

The historical rank and industry rank for Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:GLENMARK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.59   Med: 1.42   Max: 3.97
Current: 3.97

During the past years, Glenmark Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 3.97. The lowest was 0.59. And the median was 1.42.

NSE:GLENMARK's Cyclically Adjusted PS Ratio is ranked worse than
69.61% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.2 vs NSE:GLENMARK: 3.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glenmark Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹114.172. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹461.86 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 1.14 1.11 2.17 3.34

Glenmark Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 2.72 3.64 3.48 3.34

Competitive Comparison of Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1818.80/461.86
=3.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Glenmark Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=114.172/157.5517*157.5517
=114.172

Current CPI (Mar. 2025) = 157.5517.

Glenmark Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 58.829 99.841 92.834
201509 72.763 101.753 112.664
201512 71.271 102.901 109.123
201603 77.964 102.518 119.816
201606 67.674 105.961 100.623
201609 76.982 105.961 114.463
201612 87.259 105.196 130.688
201703 86.013 105.196 128.821
201706 82.519 107.109 121.381
201709 78.790 109.021 113.863
201712 76.908 109.404 110.755
201803 79.624 109.786 114.266
201806 75.491 111.317 106.846
201809 89.999 115.142 123.148
201812 88.879 115.142 121.615
201903 89.534 118.202 119.340
201906 80.870 120.880 105.404
201909 97.986 123.175 125.333
201912 93.467 126.235 116.654
202003 96.125 124.705 121.444
202006 81.811 127.000 101.492
202009 103.011 130.118 124.730
202012 97.853 130.889 117.786
202103 100.236 131.771 119.847
202106 104.367 134.084 122.633
202109 110.747 135.847 128.441
202112 111.274 138.161 126.891
202203 104.945 138.822 119.104
202206 96.354 142.347 106.646
202209 105.704 144.661 115.123
202212 108.542 145.763 117.321
202303 104.884 146.865 112.516
202306 106.195 150.280 111.333
202309 111.855 151.492 116.329
202312 87.174 152.924 89.812
202403 106.997 153.035 110.155
202406 114.243 155.789 115.536
202409 120.482 157.882 120.230
202412 117.002 158.323 116.432
202503 114.172 157.552 114.172

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glenmark Pharmaceuticals  (NSE:GLENMARK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals Business Description

Traded in Other Exchanges
Address
B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe, and the rest of the world.

Glenmark Pharmaceuticals Headlines

No Headlines